CSL (ASX:CSL) share price pops on increased dividend

The CSL (ASX: CSL) share price is higher today after the biotech announced a dramatic lift in profits and boosted dividend for the half-year.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are trending higher in early trade today following the release of the pharmaceutical giant's half-year results. At the time of writing the CSL share price is 2.38% higher at $287.89.

Profits in tip-top shape

All eyes were on the CSL share price this morning following the release of the company's results. Fortunately, the numbers did not disappoint, sending CSL shares higher in morning trade.

The most exhilarating number to come out of the half-year report was the company's bumper profit. Due to increased margins, CSL managed to deliver a 45% increase to its reported net profit after tax of US$1,810 million.

Additionally, CSL's revenue grew to US$5,739 million. Although not as substantial an increase in percentage terms, at 16.9%, the top-line growth is significant. The driving force behind the increase was a 9% lift in CSL Behring revenue and a 38% jump in Seqirus revenue.

Importantly, it appears the business segment responsible for the seasonal flu vaccine has contributed largely to the result. Seqirus added US$693 million to earnings before interest and tax – an increase of 112%.

Increased CSL dividend

As a result of the strong numbers, the CSL board increased the interim dividend by 9% to US$1.04 per share. Unfortunately, the weak US dollar to AUD means this payout is 9% lower than the prior corresponding period on a constant currency basis.

By chief executive officer and managing director Paul Perreault's account, the future for CSL remains rosy: "Demand for CSL's core plasma, and influenza vaccine products remain robust."

However, there is expected to be a lift in costs in the next half as the biotech builds its research up again, after falling due to COVID-19 vaccine development efforts.

CSL share price under the microscope

The CSL share price has taken a beating over the last year, down by around 13%. COVID-19 disruptions and vaccine development efforts weighed on the business and its usual operations.

However, in the last month, the share price has experienced a reasonable 7.6% lift as some geographies return to normal.

Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Smiling man sits in front of a graph on computer while using his mobile phone.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man lays a brick on a wall he is building with a look of joy on his face.
ETFs

This is how I would build a sound ETF portfolio from scratch

Aim for broad market exposure, keep it simple and minimize costs.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Broker Notes

These ASX 200 stocks could rise 20% to 35%

Analysts think these shares could be heading significantly higher.

Read more »

man with dog on his lap looking at his phone in his home.
Broker Notes

Buy, hold, sell: CBA, CSL, and DroneShield shares

Lets see if analysts are bullish or bearish on these popular shares.

Read more »

A kid stretches up to reach the top of the ruler drawn on the wall behind.
Opinions

This is a great place to invest $1,000 into ASX shares right now

This is the right time to invest $1,000 into ASX shares.

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Opinions

10 ASX shares I'd buy with $10,000 in 2026 to beat the market

These stocks have strong return potential over the long term.

Read more »

Multi-ethnic people looking at camera sitting at public place screaming, shouting and feeling overjoyed about their windfall, good news or sports victory.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a slightly sour end to the trading week this Friday.

Read more »

A businessman lights up the fifth star in a lineup, indicating positive share price for a top performer
Share Market News

Named: The best ASX shares to buy in January

Bell Potter thinks that double-digit returns could be on offer with these shares.

Read more »